---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-005199"
form_type: "8-K"
ticker: "TELO"
cik: "0001971532"
company_name: "Telomir Pharmaceuticals, Inc."
filed_at: "2026-02-05T23:59:59+00:00"
generated_at: "2026-05-16T04:33:57.003901+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Telomir Pharmaceuticals Reports Preclinical Data on Telomir-Zn Modulating Metal Balance

## Summary
- Telomir-Zn induced rapid intracellular zinc increase and labile ferrous iron reduction within 30 minutes in preclinical studies.
- Coordinated metal redistribution observed without loss of cell confluence or viability, supporting a non-cytotoxic mechanism.
- Findings implicate epigenetic modulation, oxidative stress reduction, and mitochondrial stabilization in cancer and aging models.
- Company advancing IND-enabling activities with planned IND submission in Q1 2026.
- Manuscript submissions initiated for peer-reviewed journals based on completed studies.

## SEC filing metadata
- accession: 0001493152-26-005199
- form_type: 8-K
- ticker: TELO
- cik: 0001971532
- company_name: Telomir Pharmaceuticals, Inc.
- filed_at: 2026-02-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1971532/000149315226005199/0001493152-26-005199-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1971532/000149315226005199/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-005199
- JSON: https://secwatch.observer/filing/0001493152-26-005199.json
- Plain text: https://secwatch.observer/filing/0001493152-26-005199.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.